ImmunoGen to Present New Data on Novel Antibody-Drug Conjugates at 60th ASH Annual Meeting
November 01 2018 - 8:01AM
Business Wire
Phase 1 Data for IMGN779 and IMGN632 to be
Highlighted in Oral Presentations at ASH
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that abstracts highlighting two of the Company’s
experimental ADC therapies, IMGN779 and IMGN632, have been accepted
for presentations at the upcoming American Society of Hematology
(ASH) Annual Meeting to be held December 1-4 in San Diego,
California.
Both IMGN779 and IMGN632 use ImmunoGen's novel
indolino-benzodiazepine payloads called IGNs, which alkylate DNA
without crosslinking. IGNs have been designed to have high potency
against acute myeloid leukemia (AML) blasts, while demonstrating
less toxicity to normal marrow progenitors than other DNA-targeting
payloads.1 IMGN779 is a next-generation anti-CD33 ADC for the
treatment of AML, currently in Phase 1 testing. IMGN632 is a
CD123-targeting ADC for hematological malignancies, including AML
and blastic plasmacytoid dendritic cell neoplasm (BPDCN), and is
also in Phase 1 testing.
In an oral presentation, safety and anti-leukemia activity
findings from the ongoing dose escalation study of IMGN779 in
patients with relapsed or refractory AML will be reported. In a
separate oral presentation, initial safety and anti-leukemia
activity findings from the dose escalation stage of the
first-in-human trial of IMGN632 will be reported. Preclinical data
related to IMGN632 will also be presented in poster sessions.
ORAL PRESENTATIONS
- Title (Abstract #26): “Maturing
Clinical Profile of IMGN779, a Next-Generation CD33-Targeting
Antibody-Drug Conjugate, in Patients with Relapsed or Refractory
Acute Myeloid Leukemia”
- Oral session 613: Saturday, December 1,
2018, 7:45am PST
- Title (Abstract #27): “A Phase I,
First-in-Human Study Evaluating the Safety and Preliminary
Antileukemia Activity of IMGN632, a Novel CD123-Targeting
Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute
Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies”
- Oral session 613: Saturday, December 1,
2018, 8:00am PST.
POSTER SESSIONS
- Title (Abstract #2647): “Synergistic
anti-leukemia activity of PARP inhibition combined with IMGN632, an
anti-CD123 antibody-drug conjugate in acute myeloid leukemia
models”
- Poster session 604: Sunday, December 2,
2018, 6:00-8:00pm PST
- Title (Abstract #3956): “Pre-clinical
efficacy of CD123-targeting antibody-drug conjugate IMGN632 in
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) models”
- Poster session 605: Monday, December 3,
2018, 6:00-8:00pm PST
Additional information can be found at www.hematology.org,
including abstracts.
ABOUT IGNs
Indolino-benzodiazepine cancer-killing agents, or IGNs, are a
new class of cancer-killing agent developed by ImmunoGen for use in
ADCs. These ultra-potent, DNA-acting IGNs alkylate DNA without
crosslinking, which preclinically has resulted in potent
anti-leukemia activity with relative sparing of normal
hematopoietic progenitor cells.
ABOUT IMGN779
IMGN779 is a novel ADC that combines a high-affinity, humanized
anti-CD33 antibody, a cleavable disulfide linker, and one of
ImmunoGen's novel indolino-benzodiazepine payloads, called IGNs,
which alkylate DNA without crosslinking, resulting in potent
preclinical anti-leukemia activity with relative sparing of normal
hematopoietic progenitor cells. IMGN779 is in Phase 1 clinical
testing for the treatment of AML.
ABOUT IMGN632
IMGN632 is a novel, anti-CD123 antibody-drug conjugate that is a
potential treatment for AML, BPDCN, and other CD123-positive
malignancies. IMGN632 uses a novel humanized anti-CD123 antibody
coupled via a peptide linker to a unique DNA-alkylating IGN
payload. In preclinical models, IMGN632 has exhibited potent
antitumor activity with a wide therapeutic index in AML, BPDCN, and
acute lymphoblastic leukemia (ALL). IMGN632 is in Phase 1 clinical
testing for the treatment of AML and BPDCN.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug
conjugates (ADCs) to improve outcomes for cancer patients. By
generating targeted therapies with enhanced anti-tumor activity and
favorable tolerability profiles, we aim to disrupt the progression
of cancer and offer our patients more good days. We call this our
commitment to “target a better now.” Our lead product candidate,
mirvetuximab soravtansine, is in a Phase 3 study for folate
receptor alpha (FRα)-positive platinum-resistant ovarian cancer,
and in Phase 1b/2 testing in combination regimens. Our novel IGN
candidates for hematologic malignancies, IMGN779 and IMGN632, are
in Phase 1 studies.
Learn more about who we are, what we do, and how we do it
at www.immunogen.com.
1Kovtun et al, abstract 768, ASH 2016.
This press release includes forward-looking statements based on
management's current expectations. For these statements, ImmunoGen
claims the protection of the safe harbor for forward-looking
statements provided by the Private Securities Litigation Reform Act
of 1995. Various factors could cause ImmunoGen's actual results to
differ materially from those discussed or implied in the
forward-looking statements, and you are cautioned not to place
undue reliance on these forward-looking statements, which are
current only as of the date of this release. It should be noted
that there are risks and uncertainties related to the development
of novel anticancer products, including risks related to
preclinical and clinical studies, their timings and results, and
the potential that earlier clinical studies may not be predictive
of future results. A review of these risks can be found in
ImmunoGen's Annual Report on Form 10-K for the fiscal year
ended December 31, 2017 and other reports filed with
the Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181101005076/en/
Investor Relations ContactImmunoGen, Inc.Sarah Kiely,
781-895-0600sarah.kiely@immunogen.comorTHRUST Strategic
CommunicationsChelcie Lister,
910-777-3049chelcie@thrustsc.comorMedia ContactImmunoGen,
Inc.Courtney O’Konek,
781-895-0600courtney.okonek@immunogen.comorFTI ConsultingRobert
Stanislaro, 212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024